Cover Image
市場調查報告書

糖酸Fluticasone(氣喘):市場預測與分析

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316082
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
糖酸Fluticasone(氣喘):市場預測與分析 Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 66 Pages
簡介

糖酸Fluticasone由GSK以「Veramyst」「Avamys」「Allermyst」等商品名在美國·歐洲·日本·澳洲推出為過敏性鼻炎的鼻內噴霧劑。此外也是Breo/Relvar的成分之一,以慢性阻塞性肺病(COPD)·氣喘治療藥在EU·日本推出。糖酸Fluticasone是具有消炎作用的合成三氟化皮質類固醇,與丙酸Fluticasone相較下,與糖皮質激素受體的結合親和力為1.7倍。

本報告提供氣喘的治療藥之一,糖酸Fluticasone的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,彙整糖酸Fluticasone的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷·治療概要
    • 診斷
    • 治療的指南,臨床診療,有代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 競爭企業的策略性評估

第6章 未滿足需求與市場機會

  • 概要
  • 為了管理嚴重氣喘的個體化治療
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 改善病人依從性
  • 降低氣喘藥物的治療費用
  • 恰當的診斷兒童氣喘

第7章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品

第8章 糖酸Fluticasone

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

GSK's fluticasone furoate is marketed as Veramyst/Avamys/Allermyst in the US, EU, Japan, and Australia for the treatment of allergic rhinitis and is formulated as a nasal spray. Fluticasone furoate is also a component of Breo/Relvar, which is marketed in the EU and Japan for the treatment of COPD and asthma. This drug is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. When compared with fluticasone propionate, fluticasone furoate has 1.7-fold greater binding affinity for the glucocorticoid receptor.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Fluticasone Furoate including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Fluticasone Furoate for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fluticasone Furoate performance
  • Obtain sales forecast for Fluticasone Furoate from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Fluticasone furoate

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Unmet Need and Opportunity in Asthma
  • Table 8: Asthma - Late Stage Pipeline, 2014
  • Table 9: Product Profile - Fluticasone Furoate
  • Table 10: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate
  • Table 11: Fluticasone Furoate Safety Profile
  • Table 12: Fluticasone Furoate SWOT Analysis, 2014
  • Table 13: Global Sales Forecast ($) for Fluticasone Furoate, 2013-2023
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
Back to Top